Current Strategies and Future Directions to Achieve Deep Molecular Response and Treatment-Free Remission in Chronic Myeloid Leukemia
Copyright © 2020 Annunziata, Bonifacio, Breccia, Castagnetti, Gozzini, Iurlo, Pregno, Stagno and Specchia..
The treatment of chronic myeloid leukemia (CML) has been radically changed by the approval of tyrosine kinase inhibitors (TKIs), which target BCR-ABL1 kinase activity. CML is now managed as a chronic disease requiring long-term treatment and close molecular monitoring. It has been shown that in a substantial number of patients who have achieved a stable deep molecular response (DMR), TKI treatment can be safely discontinued without loss of response. Therefore, treatment-free remission (TFR), through the achievement of a DMR, is increasingly regarded as a feasible treatment goal in many CML patients. However, only nilotinib has approval in this setting and a number of controversial aspects remain regarding treatment choices and timings, predictive factors, patient communication, and optimal strategies to achieve successful TFR. This narrative review aims to provide a comprehensive overview on how to optimize the path to DMR and TFR in patients with CML, and discusses recent data and future directions.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2020 |
|---|---|
| Erschienen: |
2020 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:10 |
|---|---|
| Enthalten in: |
Frontiers in oncology - 10(2020) vom: 20., Seite 883 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Annunziata, Mario [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
Chronic myeloid leukemia |
|---|
| Anmerkungen: |
Date Revised 03.11.2023 published: Electronic-eCollection Citation Status PubMed-not-MEDLINE |
|---|
| doi: |
10.3389/fonc.2020.00883 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM311609236 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM311609236 | ||
| 003 | DE-627 | ||
| 005 | 20231226201604.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231225s2020 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.3389/fonc.2020.00883 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1038.xml |
| 035 | |a (DE-627)NLM311609236 | ||
| 035 | |a (NLM)32582549 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Annunziata, Mario |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Current Strategies and Future Directions to Achieve Deep Molecular Response and Treatment-Free Remission in Chronic Myeloid Leukemia |
| 264 | 1 | |c 2020 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Revised 03.11.2023 | ||
| 500 | |a published: Electronic-eCollection | ||
| 500 | |a Citation Status PubMed-not-MEDLINE | ||
| 520 | |a Copyright © 2020 Annunziata, Bonifacio, Breccia, Castagnetti, Gozzini, Iurlo, Pregno, Stagno and Specchia. | ||
| 520 | |a The treatment of chronic myeloid leukemia (CML) has been radically changed by the approval of tyrosine kinase inhibitors (TKIs), which target BCR-ABL1 kinase activity. CML is now managed as a chronic disease requiring long-term treatment and close molecular monitoring. It has been shown that in a substantial number of patients who have achieved a stable deep molecular response (DMR), TKI treatment can be safely discontinued without loss of response. Therefore, treatment-free remission (TFR), through the achievement of a DMR, is increasingly regarded as a feasible treatment goal in many CML patients. However, only nilotinib has approval in this setting and a number of controversial aspects remain regarding treatment choices and timings, predictive factors, patient communication, and optimal strategies to achieve successful TFR. This narrative review aims to provide a comprehensive overview on how to optimize the path to DMR and TFR in patients with CML, and discusses recent data and future directions | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Review | |
| 650 | 4 | |a chronic myeloid leukemia | |
| 650 | 4 | |a deep molecular response | |
| 650 | 4 | |a optimal strategies | |
| 650 | 4 | |a treatment-free remission | |
| 650 | 4 | |a tyrosine kinase inhibitors | |
| 700 | 1 | |a Bonifacio, Massimiliano |e verfasserin |4 aut | |
| 700 | 1 | |a Breccia, Massimo |e verfasserin |4 aut | |
| 700 | 1 | |a Castagnetti, Fausto |e verfasserin |4 aut | |
| 700 | 1 | |a Gozzini, Antonella |e verfasserin |4 aut | |
| 700 | 1 | |a Iurlo, Alessandra |e verfasserin |4 aut | |
| 700 | 1 | |a Pregno, Patrizia |e verfasserin |4 aut | |
| 700 | 1 | |a Stagno, Fabio |e verfasserin |4 aut | |
| 700 | 1 | |a Specchia, Giorgina |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Frontiers in oncology |d 2011 |g 10(2020) vom: 20., Seite 883 |w (DE-627)NLM218189583 |x 2234-943X |7 nnns |
| 773 | 1 | 8 | |g volume:10 |g year:2020 |g day:20 |g pages:883 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.3389/fonc.2020.00883 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 10 |j 2020 |b 20 |h 883 | ||